



Clinical **SCIENCE**

AN INTERNATIONAL JOURNAL OF CLINICAL & MOLECULAR INVESTIGATION

VOLUME 112 : 2007

EDITORIAL BOARD

Editor-in-Chief

Anna Dominiczak OBE

Reviews Editor

Rhian Touyz

Associate Editors

David Adams

Nigel Brunskill

Philip Calder

Stephen Holgate

Jonathan Lamb

Chim Lang

Nilesh Samani

Gerald Watts

Clinton Webb

Hugh Willison

Editors

Lawrie Beilin

Louise Burrell

Christian Delles

Jean-Francois Dufour

Peter Emery

Subrata Ghosh

Aroon Hingorani

Richard James

Anna Kurdowska

Maria Teresa La Rovere

Mhairi Macrae

Janice Marshall

Kevin McCully

Gary McVeigh

James Meschia

John Monson

Patricia Munroe

Chris Newman

Philip Newsholme

Kevin O'Shaughnessy

Aled Phillips

Michael Polkey

Josep Redon

Naveed Sattar

Åke Sjöholm

Allan Sniderman

Mark Swain

Ingo Tamm

John Wark

Brenda Williams

Dominic Withers

Ian Young

**Published by Portland Press on behalf of the
Biochemical Society**

© **The Biochemical Society 2007**

ISSN 0143-5221

Printed in Great Britain by the Charlesworth Group, Wakefield

EDITORIAL ADVISORY PANEL

- C. Austin (Manchester)
D. Bhatnagar (Oldham)
I. Biaggioni (Nashville, TN)
C. E. Brightling (Leicester)
A. Burt (Newcastle upon Tyne)
D. Callen (Adelaide, S. Aus.)
J. D. Cameron (Dandenong, Vic.)
A. Carter (Leeds)
J. P. F. Chin-Dusting (Melbourne)
P. Chowienczyk (London)
S. Duthie (Aberdeen)
K. Evans (Stafford)
A. Ferrante (North Adelaide)
C. Ferri (L'Aquila)
J. Floras (Toronto)
G. A. Ford (Newcastle upon Tyne)
D. Freeman (Glasgow)
L.-M. Gan (Goteburg)
B. Garner (Sydney)
G. J. Gibson (Newcastle upon Tyne)
S. Gough (Birmingham)
A. Graham (Glasgow)
G. Grassi (Milan)
D. J. Green (Nedlands, WA)
F. R. Green (Oxford)
M. Grimm (Kogarah, NSW)
N. Haites (Aberdeen)
S. Hope (Melbourne)
J. D. Imig (Augusta, GA)
E. W. Inscho (Augusta, GA)
B. Jilma (Vienna)
J. T. Kielstein (Stanford, CA)
W. Koch (Munich)
L. Kritharides (Sydney)
D. S. Kumararatne (Cambridge)
T. Kuo (Hualien)
P. Little (Melbourne)
D. Lobo (Nottingham)
- R. A. Malik (Manchester)
J. Mullins (Edinburgh)
S. Nagueh (Houston, TX)
L. Ng (Leicester)
T. Nyström (Stockholm)
M. J. O'Leary (Sydney)
T. Omland (Oslo)
G. Parati (Milan)
S. Phillips (Hamilton)
G. Piccirillo (Rome)
M. Rademaker (Christchurch, NZ)
J. Rhodes (Liverpool)
R. Rush (Adelaide)
M. Schillinger (Vienna)
F. C. Schmalstieg, Jr (Galveston)
T. Shimosawa (Tokyo)
C. C. Shoulders (London)
S. S. Smyth (Chapel Hill, NC)
I. Squire (Leicester)
J. Staessen (Leuven)
H. Stauss (Berlin)
I. Striz (Prague)
D.-F. Su (Shanghai)
S. R. Thomas (Sydney)
N. C. Thomson (Glasgow)
V. Thongboonkerd (Bangkok)
H. Tomiyama (Tokyo)
M. van der Giet (Berlin)
J. J. Van Lieshout (Amsterdam)
M. Verma (Bethesda)
S. Watts (East Lansing)
M. Weiss (Munich)
J. Wernerman (Huddinge)
M. J. White (Birmingham)
J. Wilson (Bankstown, NSW)
R. Woodman (Perth, WA)
C. Zhang (Memphis)
J. Zicha (Prague)

A U T H O R I N D E X

- A**gelaki, M. G. 385–391
 Ahlman, B. 499–506
 Alba, J. S. 241–250
 Alcaraz, A. 167–174
 Alfakih, K. 617–624
 Amin, M. 305–314
 Amon, M. 429–440
 Andréasson, A. 363–373
 Asico, L. D. 583–597
 Asselbergs, F. W. 291–298
 Atucha, N. M. 167–174
- B**ail, D. H. L. 315–324
 Balmforth, A. J. 617–624
 Baltogiannis, G. G. 385–391
 Barbe, M. F. 305–314
 Barr, A. E. 305–314
 Barrett, E. J. 457–466
 Barrett, P. H. R. 625
 Beckmann, M. W. 51–57
 Bellien, J. 393–401
 Berlanga, J. 241–250
 Bielak, L. F. 175–182
 Bilderbeek-Beckers, M. A. L. 123–130
 Bogaerts, Y. 281–289
 Bourkaib, R. 393–401
 Bradding, P. 411–416
 Bradley, E. A. 457–466
 Braund, P. 411–416
 Bredie, S. J. H. 131–139
 Brismar, K. 363–373
 Brouwers, M. C. G. J. 123–130
 Brüllmann, B. 315–324
 Burnier, M. 337–344
 Buurman, W. A. 527–532
- C**ampbell, R. I. 441–447
 Carp, S. J. 305–314
 Chambers, T. J. 567–575
 Chan, D. C. 625
 Charles, C. J. 485–491
 Cibrian, D. 241–250
 Clark, M. G. 457–466
- Coenegrachts, K. L. 281–289
 Cooper, J. A. 617–624
 Curi, R. 59–67
- D**avies, J. E. 251–256, 477–484
 Davies, T. S. 441–447
 Dean, C. B. 517–525
 de Bruin, T. W. A. 123–130
 de Graaf, J. 131–139, 507–516
 Dejong, C. H. C. 527–532
 Dengel, D. R. 493–498
 Denys, B. G. 281–289
 Deutz, N. E. P. 527–532
 De Vriese, A. S. 281–289
 Di Benedetto, G. 257–263
 Di Mario, L. 217–227
 Dominguez, H. 241–250
 Drukarch, B. 1–25
 Duarte, J. N. 183–191
- E**fendic, S. 345–351
 Eguchi, S. 417–428
 Eisner, G. M. 583–597
 Elaiopoulos, D. A. 385–391
 Elofsson, S. 363–373
 Eltchaninoff, H. 393–401
 Erni, D. 429–440
- F**abiani, J. N. 229–239
 Fan, Q. 299–304
 Fioretti, F. 229–239
 Flatman, P. W. 203–216
 Flavell, D. M. 617–624
 Fotiadis, D. I. 385–391
 Frank, G. D. 417–428
 Fredriksson, K. 499–506
 Frenneaux, M. P. 441–447
 Fujino, N. 577–582
 Fuller, K. 567–575
 Furukawa, K.-I. 113–121
- G**alisteo, M. 183–191
 Garcia, D. 241–250
- García-Estañ, J. 167–174
 Geim, A. I. 315–324
 Georgi, M. 429–440
 Georgieva, A. M. 123–130
 Godeau, G. 229–239
 Goodall, A. H. 411–416
 Goto, Y. 43–49
 Groothuis, J. T. 193–201
 Guevara, L. 241–250
 Guillén, G. 241–250
- H**aeffliger, I. 337–344
 Hall, A. S. 617–624
 Hammarqvist, F. 499–506
 Harder, Y. 429–440
 Hayashi, K. 577–582
 Heinzlmann, U. 315–324
 Henderson, N. C. 265–280
 Higuchi, S. 417–428
 Hirata, Y. 607–616
 Hitchcock, C. L. 517–525
 Hogarth, A. J. 353–361
 Holness, M. J. 93–111
 Hopman, M. T. E. 193–201
 Hou, M.-C. 533–542
 Hou, Y.-p. 299–304
 Hu, Y. 599–606
 Huang, Y.-T. 533–542
 Huang, Z. 69–76
 Humphries, S. E. 617–624
 Hunter, D. J. 291–298
- J**acob, M. 393–401
 Ino, H. 577–582
 Iredale, J. P. 265–280
 Iwata, H. 607–616
 Iyú, D. 167–174
- J**acek, M. 557–565
 Jansson, L. 69–76, 345–351
 Ji, J. 625
 Jia, W. 599–606
 Jimenez, R. 183–191
 Joannides, R. 393–401
 Johnson, A. G. 625
 Jose, P. A. 583–597
- K**anda, M. 43–49
 Katoh, H. 577–582
 Kautzky-Willer, A. 257–263
 Keane, D. 27–42
 Kelly, A. S. 493–498
 Kelly, D. 251–256
 Kennedy, C. R. J. 325–335
 Khan, S. Q. 251–256
 Kinoshita, H. 43–49
 Kirstein, B. 567–575
 Klaude, M. 499–506
 Klimcakova, E. 557–565
 Kolettis, T. M. 385–391
 Konno, T. 577–582
 Konsman, J. P. 1–25
 Kovacicova, M. 557–565
 Kovacova, Z. 557–565
 Krediet, C. T. P. 157–165
 Kuda, O. 557–565
 Kugiyama, K. 607–616
 Kullo, I. J. 175–182
- L**am, E. Y. M. 467–475
 Lau, H. K. 449–456
 Lee, F.-Y. 533–542
 Lee, S.-D. 533–542
 Lee, T.-Y. 533–542
 Lei, L. 599–606
 Lekander, M. 363–373
 Levy, A. S. 403–409
 Lin, H.-C. 533–542
 Lin, J. 599–606
 Linzer, M. 157–165
 Littman, B. H. 217–227
 Liu, L. 599–606
 Liu, M.-b. 299–304
 López-Mola, E. 241–250
 López-Saura, P. 241–250
 Luiking, Y. C. 527–532
- M**acDonald, M. J. 403–409
 Mackintosh, A. F. 353–361
 Maillard, M. 337–344
 Malik, A. R. 175–182

- Mangino, M. 411–416
Marincola, F. M. 217–227
Martin, T. J. 77–91
Martínez-Prieto, C.
167–174
Mary, D. A. S. G. 353–361
Masuta, E. 577–582
Mathsson, L. 363–373
Maznyczka, A. 411–416
McCartney, N. 403–409
McGowan, C. L. 403–409
Menger, M. D. 429–440
Meurer, B. 51–57
Michaud, J.-L. R. 325–335
Mitsi, A. C. 385–391
Miyazaki, S. 43–49
Montgomery, H. E.
617–624
Morbiducci, U. 257–263
Morgan, N. G. 27–42
Motomura, S. 113–121
- N**agai, R. 607–616
Nagaya, N. 43–49
Nakamura, K. 607–616
Nattermann, J. 141–155
Newman, J. M. B. 457–466
Newsholme, P. 27–42
Ng, L. L. 251–256, 477–484
Nielsen, J. D. 517–525
Nolan, R. P. 449–456
Nonogi, H. 43–49
- O**'Brien, R. J. 477–484
Ohtsu, H. 417–428
Ooi, E. M. M. 625
Ortiz, M. C. 167–174
Östenson, C.-G. 345–351
Otton, R. 59–67
- P**acini, G. 257–263
Pai, J. K. 291–298
Palmer, T. 411–416
Panarello, F. 337–344
Pechere-Bertschi, A.
337–344
- Perez, B. 241–250
Pérez-Vizcaíno, F. 183–191
Peysner, P. A. 175–182
Pires, J. 59–67
Pittet, B. 429–440
Plebani, M. 217–227
Polak, J. 557–565
Prior, J. C. 517–525
- Q**uinn, P. 251–256
Quinn, P. A. 477–484
- R**ademaker, M. T. 485–491
Rattigan, S. 457–466
Reid, G. J. 449–456
Rexrode, K. M. 291–298
Richards, A. M. 485–491
Richards, S. M. 457–466
Rickard, A. J. 467–475
Rimm, E. B. 291–298
Roberts, M. K. 457–466
Rodriguez, A. 241–250
Rönnelid, J. 363–373
Rooyackers, O. 499–506
Rosa, V. 167–174
Rosado, J. A. 167–174
Rücker, M. 429–440
Rupin, A. 229–239
Rye, K.-A. 625
- S**akai, Y. 607–616
Sakamoto, Y. 577–582
Samani, N. J. 411–416
Samcova, E. 557–565
Sánchez, M. 183–191
Sansilvestri-Morel, P.
229–239
Sata, M. 607–616
Savoia, C. 375–384
Scheuer, C. 429–440
Schiffrin, E. L. 375–384
Schiller, S. 315–324
Schlembach, D. 51–57
Schramm, R. 429–440
Sebela, M. 557–565
Seeman, E. 77–91
- Seidelin, P. H. 449–456
Sengenberger, R. 51–57
Senni, K. 229–239
Seralena, A. 241–250
Seya, K. 113–121
Sheedy II, P. F. 175–182
Shirai, H. 417–428
Sinaiko, A. R. 493–498
Sivananthan, M. 617–624
Sjöholm, Å. 69–76
Sniderman, A. D. 131–139
Song, F. 599–606
Spengler, U. 141–155
Squire, I. B. 477–484
Stalenhoef, A. F. H.
131–139, 507–516
Steger, V. 315–324
Steinberger, J. 493–498
Stich, V. 557–565
Strick, R. 51–57
Strissel, P. L. 51–57
Sugden, M. C. 93–111
Sun, X. 599–606
Sunaric-Megevand, G.
337–344
Suzuki, H. 417–428
Svensson, A. M. 345–351
- T**almud, P. J. 617–624
ter Avest, E. 131–139,
507–516
ter Woerds, W. 193–201
Thuillez, C. 393–401
Tjäder, I. 499–506
Tobin, M. 411–416
Tsalikakis, D. G. 385–391
Tschakovsky, M. E. 157–165
Tsubokawa, T. 577–582
Tura, A. 257–263
Turner, S. T. 175–182
- U**chiyama, K. 577–582
Undén, A.-L. 363–373
- V**an Dam, A.-M. 1–25
- van der Kallen, C. J. H.
123–130
van Dijk, N. 157–165,
193–201
van Greevenbroek, M. M. J.
123–130
Vera, R. 183–191
Verbeuren, T. J. 229–239
Vigna, Y. M. 517–525
Villar, I. C. 183–191
Vispo, N. S. 241–250
Vissers, Y. L. J. 527–532
Vitkova, M. 557–565
Vollus, G. C. 457–466
von Meyenfeldt, M. F.
527–532
- W**alker, C. G. 93–111
Wallner, W. 51–57
Wang, Y.-W. 533–542
Watts, G. F. 625
Welters, H. J. 27–42
Wernerman, J. 499–506
White, M. J. 441–447
Whittaker, A. 411–416
Wiegman, A. 131–139
Wieling, W. 157–165,
193–201
Williams, L. A. 517–525
Wilund, K. R. 543–555
Winter, K. A. 305–314
Wu, J.-L. 299–304
- Y**amagishi, M. 577–582
Yang, Y.-Y. 533–542
Yao, Y. 599–606
Yasuda, S. 43–49
Yin, B.-I. 299–304
Young, M. J. 467–475
- Z**ariwala, M. G. 93–111
Zarzuolo, A. 183–191
Zeng, C. 583–597
Zhang, L. 299–304
Zhang, M. 583–597
Ziemer, G. 315–324

S U B J E C T I N D E X

- A**cute coronary syndrome
myotrophin, N-terminal pro-B-type natriuretic peptide (NTproBNP) 251–256
- Adiponectin
insulin resistance, weight loss 557–565
- Age
behaviour, self-rated health 363–373
- Aging
familial combined hyperlipidaemia (FCH), obesity 131–139
ischaemia, necrosis 429–440
- Angiogenesis
ischaemia, prostacyclin agonist (ONO-1301) 607–616
- Angiogenic factor
intrauterine growth restriction (IUGR), pregnancy 51–57
- Angiotensin II type I receptor (AT₁ receptor)
cardiovascular disease, signal transduction 417–428
flow-mediated dilation (FMD), nitric oxide synthase (NOS) 393–401
- Antioxidant
DNA damage, Type 2 diabetes 599–606
- Apoptosis
lymphocyte, starvation 59–67
- Arachidonate
5-lipoxygenase-activating protein (ALOX5AP)
leukotriene, myocardial infarction 411–416
- Arginine
post-operative response, tumour 527–532
- Arterial hypotension
normal pressure glaucoma, sodium handling 337–344
- Arterial stiffness
isometric exercise, muscle metaboreflex 441–447
- Atherosclerosis
cardiovascular risk prediction, non-invasive measurement 507–516
- Autonomic nervous system
gender, muscle sympathetic nerve activity 353–361
- B**ile duct ligation
calcium signalling, platelet 167–174
- β -Blocker
Fas/Fas ligand, left ventricular function 299–304
- Blood flow
pancreatic islet, vasoactive drug 69–76
- Blood perfusion
glucagon-like peptide-1 (GLP-1), Type 2 diabetes 345–351
- Blood pressure
flow-mediated dilation (FMD), isometric exercise 403–409
orthostatic hypotension, syncope 157–165
- Blood–brain barrier
(peri)vascular cell, pro-inflammatory cytokine 1–25
- Bone
osteoporosis, remodelling 77–91
- Bone resorption
enzymatic regulation, osteoclast 567–575
- Brachial artery diameter
coronary artery calcium, vasodilation 175–182
- Brain natriuretic peptide (BNP)
cardiac function, extracorporeal circulation 315–324
- C**alcium signalling
bile duct ligation, platelet 167–174
- Cancer
nitric oxide, post-operative response 527–532
- Cannabinoid receptor
cirrhosis, eicosanoid 533–542
- Cardiac fibrosis
glucocorticoid, mineralocorticoid receptor 467–475
- Cardiac function
brain natriuretic peptide (BNP), extracorporeal circulation 315–324
- Cardiac myocyte
cytochrome c, mitochondrial cGMP 113–121
- Cardioprotection
growth-hormone-releasing peptide 6 (GHRP6), myocardial infarction 241–250
- Cardiovascular disease
angiotensin II type I receptor (AT₁ receptor), signal transduction 417–428
exercise, inflammation 543–555
- Cardiovascular risk prediction
atherosclerosis, non-invasive measurement 507–516
- Cellular adhesion molecular
coronary artery disease, gene polymorphism 291–298
- Central nervous system
dopamine, hypertension 583–597
- Cirrhosis
eicosanoid, cannabinoid receptor 533–542
hepatitis C virus (HCV), immunopathogenesis 141–155
- Clinical research
drug target, translational medicine 217–227
- Conjugated equine oestrogen (CEE)
hot flush, medroxyprogesterone (MPA) 517–525
- Coronary artery calcium
brachial artery diameter, vasodilation 175–182
- Coronary artery disease
C-reactive protein (CRP), vagal heart rate control 449–456

- galectin-2 gene (*LGALS2*),
lymphotoxin- α gene (*LTA*)
291–298
- left ventricular hypertrophy,
lipoprotein lipase gene
617–624
- Cotransporter
hypertension, with no lysine kinase
(*WNK*) 203–216
- C-reactive protein (CRP)
coronary artery disease, vagal
heart rate control
449–456
- Cytochrome *c*
cardiac myocyte, mitochondrial
cGMP 113–121
- D** Diabetes
diet, obesity 93–111
hypertension, inflammation
375–384
- Diet
diabetes, obesity 93–111
- DNA damage
antioxidant, Type 2 diabetes
599–606
- Dopamine
central nervous system,
hypertension 583–597
- Drug target
translational medicine, clinical
research 217–227
- E** Eicosanoid
cannabinoid receptor, cirrhosis
533–542
- Endothelial dysfunction
hypertension, phytoestrogen
183–191
- Endothelial function
glucose loading, overweight
children 493–498
- Endothelial nitric oxide synthase
(eNOS)
NADPH oxidase, phytoestrogen
183–191
- Enzymatic regulation
bone resorption, osteoclast
567–575
- Exercise
cardiovascular disease,
inflammation 543–555
- Extracellular matrix
matrix metalloproteinase
(MMP), varicose vein
229–239
- Extracorporeal circulation
brain natriuretic peptide
(BNP), cardiac function
315–324
- F** Familial combined hyperlipidaemia
(FCH)
aging, obesity 131–139
fatty liver, visceral adiposity
123–130
- Fas/Fas ligand
 β -blocker, left ventricular function
299–304
- Fatty liver
familial combined hyperlipidaemia
(FCH), visceral adiposity
123–130
- Flow mediated dilation (FMD)
angiotensin II type I receptor
(AT₁ receptor), nitric oxide
synthase (NOS)
393–401
blood pressure, isometric exercise
403–409
- G** Galectin-2 gene (*LGALS2*)
coronary artery disease,
lymphotoxin- α gene (*LTA*)
291–298
- Gender
autonomic nervous system, muscle
sympathetic nerve activity
353–361
inflammatory cytokine, self-rated
health 363–373
- Genetic algorithm
insulin sensitivity, minimal model
257–263
- Glomerular filtration barrier
podocyte, slit diaphragm complex
325–335
- Glucagon-like peptide-1 (GLP-1)
blood perfusion, Type 2 diabetes
345–351
- Glucocorticoid
cardiac fibrosis, mineralocorticoid
receptor 467–475
- Glucose loading
endothelial function, overweight
children 493–498
- Glucose uptake
insulin, muscle 457–466
- Growth hormone (GH)
myocardial infarction, ventricular
arrhythmia 385–391
- Growth-hormone-releasing peptide 6
(GHRP6)
cardioprotection, myocardial
infarction 241–250
- H** Hepatitis C virus (HCV)
cirrhosis, immunopathogenesis
141–155
- Hot flush
conjugated equine oestrogen (CEE),
medroxyprogesterone (MPA)
517–525
- Hypertension
cotransporter, with no lysine kinase
(*WNK*) 203–216
diabetes, inflammation 375–384
dopamine, central nervous system
583–597
endothelial dysfunction,
phytoestrogen 183–191
- Hypertrophic cardiomyopathy
left ventricular hypertrophy,
negative T wave 577–582
- Hypotension
neurohumoral response, urocortin
485–491
- I** Immunopathogenesis
cirrhosis, hepatitis C virus (HCV)
141–155
- Inflammation
cardiovascular disease, exercise
543–555
diabetes, hypertension 375–384
liver fibrosis, myofibroblast
265–280
- Inflammatory biomarker
musculoskeletal disorder, overuse
305–314
- Inflammatory cytokine
gender, self-rated health 363–373
- Insulin
glucose uptake, muscle 457–466
- Insulin resistance
adiponectin, weight loss 557–565
- Insulin sensitivity
genetic algorithm, minimal model
257–263
- Intrauterine growth restriction
(IUGR)
angiogenic factor, pregnancy
51–57
- Ischaemia
aging, necrosis 429–440
angiogenesis, prostacyclin agonist
(ONO-1301) 607–616

- Isometric exercise
arterial stiffness, muscle
metaboreflex 441–447
blood pressure, flow-mediated
dilation (FMD) 403–409
- L**eft ventricular function
 β -blocker, Fas/Fas ligand 299–304
- Left ventricular hypertrophy
coronary heart disease, lipoprotein
lipase gene 617–624
hypertrophic cardiomyopathy,
negative T wave 577–582
- Leg vascular conductance
orthostatic intolerance, physical
counter-manoevre 193–201
- Leukotriene
arachidonate
5-lipoxygenase-activating protein,
myocardial infarction 411–416
- Lipoprotein lipase gene
coronary heart disease, left
ventricular hypertrophy 617–624
- Liver fibrosis
inflammation, myofibroblast
265–280
- Lymphocyte
apoptosis, starvation 59–67
- Lymphotoxin- α gene (*LTA*)
coronary artery disease, galectin-2
gene (*LGALS2*) 291–298
- M**atrix metalloproteinase (MMP)
extracellular matrix, varicose vein
229–239
myocardial infarction, statin 43–49
- Medroxyprogesterone (MPA)
conjugated equine oestrogen (CEE),
hot flush 517–525
- Metabolism
non-esterified fatty acid, pancreatic
 β -cell 27–42
- Microvascular perfusion
aging, ischaemic tolerance
429–440
- Mineralocorticoid receptor
cardiac fibrosis, glucocorticoid
467–475
- Minimal model
genetic algorithm, insulin sensitivity
257–263
- Mitochondrial cGMP
cardiac myocyte, cytochrome c
113–121
- Muscle
glucose uptake, insulin 457–466
- Muscle metaboreflex
arterial stiffness, isometric exercise
441–447
- Muscle sympathetic nerve activity
autonomic nervous system, gender
353–361
- Musculoskeletal disorder
inflammatory biomarker, overuse
305–314
- Myocardial infarction
arachidonate
5-lipoxygenase-activating protein,
leukotriene 411–416
cardioprotection, growth-hormone-
releasing peptide 6 (GHRP6)
241–250
growth hormone (GH), ventricular
arrhythmia 385–391
matrix metalloproteinase (MMP),
statin 43–49
oxygen-related protein 150
(ORP150), prognosis 477–484
- Myofibroblast
inflammation, liver fibrosis 265–280
- Myotrophin
acute coronary syndrome,
N-terminal pro-B-type
natriuretic peptide 251–256
- N**ecrosis
aging, ischaemia 429–440
- Negative T wave
hypertrophic cardiomyopathy, left
ventricular hypertrophy 577–582
- Neurohumoral response
hypotension, urocortin 485–491
- Night sweats
hot flush, surgical menopause
517–525
- Nitric oxide synthase (NOS)
angiotensin II type I receptor (AT₁
receptor), flow-mediated dilation
(FMD) 393–401
- Non-esterified fatty acid
metabolism, pancreatic β -cell
27–42
- Non-invasive measurement
atherosclerosis, cardiovascular risk
prediction 507–516
- Normal pressure glaucoma
arterial hypotension, sodium
handling 337–344
- N-terminal pro-B-type natriuretic
peptide (NTproBNP)
acute coronary syndrome,
myotrophin 251–256
- O**besity
aging, familial combined
hyperlipidaemia (FCH) 131–139
diabetes, diet 93–111
- Orthostatic hypotension
blood pressure, syncope 157–165
- Orthostatic intolerance
leg vascular conductance, physical
counter-manoevre 193–201
- Osteoclast
bone resorption, enzymatic
regulation 567–575
- Osteoporosis
bone, remodelling 77–91
- Overuse
inflammatory biomarker,
musculoskeletal disorder
305–314
- Overweight children
endothelial function, glucose
loading 493–498
- Oxygen-related protein 150
(ORP150)
myocardial infarction, prognosis
477–484
- P**ancreatic islet
blood flow, vasoactive drug 69–76
- Pancreatic β -cell
metabolism, non-esterified fatty
acid 27–42
- (Peri)vascular cell
blood–brain barrier,
pro-inflammatory cytokine 1–25
- Physical counter-manoevre
leg vascular conductance,
orthostatic intolerance 193–201
- Phytoestrogen
endothelial dysfunction,
hypertension 183–191
- Platelet
bile duct ligation, calcium signalling
167–174
- Podocyte
glomerular filtration barrier, slit
diaphragm complex 325–335
- Post-operative response
arginine, tumour 527–532
- Pregnancy
angiogenic factor, intrauterine
growth restriction (IUGR)
51–57
- Prognosis
myocardial infarction,
oxygen-related protein 150
(ORP150) 477–484

- Pro-inflammatory cytokine
blood–brain barrier, (peri)vascular
cell 1–25
- Prostacyclin agonist (ONO-1301)
angiogenesis, ischaemia
607–616
- Proteasome
sepsis, skeletal muscle
499–506
- R**emodelling
bone, osteoporosis 77–91
- S**aphenous vein
skin, varicose vein 229–239
- Sarcoidosis
steroid resistance, tumour
necrosis factor- α (TNF- α)
281–289
- Self-rated health
gender, inflammatory cytokine
363–373
- Sepsis
proteasome, skeletal muscle
499–506
- Signal transduction
angiotensin II type I receptor (AT₁
receptor), cardiovascular disease
417–428
- Skeletal muscle
proteasome, sepsis 499–506
- Slit diaphragm complex
glomerular filtration barrier,
podocyte 325–335
- Sodium handling
arterial hypotension, normal
pressure glaucoma 337–344
- Starvation
apoptosis, lymphocyte 59–67
- Statin
matrix metalloproteinase (MMP),
myocardial infarction 43–49
- Steroid resistance
sarcoidosis, tumour necrosis
factor- α (TNF- α) 281–289
- Syncope
blood pressure, orthostatic
hypotension 157–165
- T**ranslational medicine
clinical research, drug target
217–227
- Tumour
arginine, post-operative response
527–532
- Tumour necrosis factor- α (TNF- α)
sarcoidosis, steroid resistance
281–289
- Type 2 diabetes
antioxidant, DNA damage 599–606
blood perfusion, glucagon-like
peptide-I (GLP-I) 345–351
- U**rocortin
hypotension, neurohumoral
response 485–491
- V**agal heart rate control
coronary artery disease,
C-reactive protein (CRP)
449–456
- Varicose vein
extracellular matrix, matrix
metalloproteinase (MMP)
229–239
- Vasoactive drug
blood flow, pancreatic islet
69–76
- Vasodilation
brachial artery diameter, coronary
artery calcium 175–182
- Ventricular arrhythmia
growth hormone (GH), myocardial
infarction 385–391
- Visceral adiposity
familial combined hyperlipidaemia
(FCH), fatty liver 123–130
- W**eight loss
adiponectin, insulin resistance
557–565
- With no lysine kinase (WNK)
cotransporter, hypertension
203–216